Related Experiment Video
Updated: Dec 25, 2025

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Lavinia Morosi1, Cristina Matteo1, Tommaso Ceruti1
1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Department of Oncology.
Abstract:
Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel. Methods: Different inorganic nanoparticles were tested as matrices to visualize the PARP inhibitors (PARPi) niraparib and olaparib. Normalization by deuterated internal standard and a custom preprocessing pipeline were applied to achieve a reliable single pixel quantification of the two drugs in human ovarian tumors from treated mice. Results: A quantitative method to visualize niraparib and olaparib in tumor tissue of treated mice was set up and validated regarding precision, accuracy, linearity, repeatability and limit of detection. The different tumor penetration of the two drugs was visualized by MSI and confirmed by LC-MS/MS, indicating the homogeneous distribution and higher tumor exposure reached by niraparib compared to olaparib. On the other hand, niraparib distribution was heterogeneous in an ovarian tumor model overexpressing the multidrug resistance protein P-gp, a possible cause of resistance to PARPi. Conclusions: The current work highlights for the first time quantitative distribution of PAPRi in tumor tissue. The different tumor distribution of niraparib and olaparib could have important clinical implications. These data confirm the validity of MSI for spatial quantitative measurement of drug distribution providing fundamental information for pharmacokinetic studies, drug discovery and the study of resistance mechanisms.
Insights
Mass spectrometry imaging visualizes anticancer drug distribution in tumors. Niraparib showed more homogeneous distribution than olaparib, offering insights into drug efficacy and resistance mechanisms.
Area of Science:
- Oncology
- Pharmacology
- Analytical Chemistry
Background:
- Optimal anticancer drug distribution within tumors is crucial for therapeutic efficacy.
- Traditional methods like LC-MS/MS lack spatial information on drug concentration.
- Mass spectrometry imaging (MSI) offers high spatial resolution and specificity for visualizing drug distribution.
Purpose of the Study:
- To develop and validate a quantitative MSI method for visualizing PARP inhibitors (PARPi) niraparib and olaparib distribution in ovarian tumors.
- To compare the intratumor distribution of niraparib and olaparib using MSI.
- To investigate the impact of P-glycoprotein (P-gp) expression on niraparib distribution.
Main Methods:
- Inorganic nanoparticles were used as matrices for MSI analysis of niraparib and olaparib.
- Deuterated internal standards and a custom preprocessing pipeline were employed for single-pixel quantification.
- Quantitative MSI data were validated for precision, accuracy, linearity, repeatability, and limit of detection.
Main Results:
- A validated quantitative MSI method was established for niraparib and olaparib in mouse ovarian tumors.
- MSI revealed differential tumor penetration, with niraparib showing more homogeneous distribution and higher exposure than olaparib.
- Niraparib distribution was heterogeneous in tumors overexpressing P-gp, suggesting a potential resistance mechanism.
Conclusions:
- This study demonstrates the first quantitative spatial distribution of PARPi in tumor tissues using MSI.
- The distinct tumor distribution patterns of niraparib and olaparib have potential clinical implications for treatment strategies.
- MSI is a valuable tool for pharmacokinetic studies, drug discovery, and understanding drug resistance mechanisms.
More Related Videos
08:08Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
06:47Expanding the Comprehension of the Tumor Microenvironment using Mass Spectrometry Imaging of Formalin-Fixed and Paraffin-Embedded Tissue Samples
Published on: June 29, 2022